



PTO/SB/08B (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known			
		Application Number	09/826,212		
		Filing Date	April 5, 2001		
		First Named Inventor	Ying-Fei Wei		
		Art Unit	1646		
		Examiner Name	Eileen O'Hara		
Sheet	1	of	1	Attorney Docket Number	1488.1280006/EKS/EJH

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
COA	NPL1	Badley, A.D., <i>et al.</i> , "Upregulation of Fas Ligand Expression by Human Immunodeficiency Virus in Human Macrophages Mediates Apoptosis of Uninfected T Lymphocytes," <i>J. Virol.</i> 70:199-206, American Society for Microbiology (January 1996)	
	NPL2	Han, L.-H., <i>et al.</i> , "Detection of soluble TRAIL in HBV infected patients and its clinical implications," <i>World J. Gastroenterol.</i> 8:1077-1080, The WJG Press (December 2002)	
	NPL3	Jeremias, I., <i>et al.</i> , "TRAIL/Apo-2-ligand-induced apoptosis in human T cells," <i>Eur. J. Immunol.</i> 28:143-152, Wiley-VCH Verlag GmbH (January 1998)	
	NPL4	Miura, Y., <i>et al.</i> , "Critical Contribution of Tumor Necrosis Factor-related Apoptosis-inducing Ligand (TRAIL) to Apoptosis of Human CD4 ⁺ T Cells in HIV-1-infected hu-PBL-NOD-SCID Mice," <i>J. Exp. Med.</i> 193:651-659, The Rockefeller University Press (March 2001)	
	NPL5	Miura, Y. and Koyanagi, Y., "Death ligand-mediated apoptosis in HIV infection," <i>Rev. Med. Virol.</i> 15:169-178, John Wiley & Sons, Ltd. (March 2005)	
	NPL6	Okada, H., <i>et al.</i> , "Extensive lymphopenia due to apoptosis of uninfected lymphocytes in acute measles patients," <i>Arch. Virol.</i> 145:905-920, Springer-Verlag (May 2000)	
	NPL7	Roe, M.F.E., <i>et al.</i> , "Lymphocyte apoptosis in acute respiratory syncytial virus bronchiolitis," <i>Clin. Exp. Immunol.</i> 137:139-145, Blackwell Publishing Ltd. (July 2004)	
✓	NPL8	Secchiero, P., <i>et al.</i> , "Human herpesvirus 7 induces the functional up-regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modulation in CD4 ⁺ T cells," <i>Blood</i> 98:2474-2481, The American Society of Hematology (October 2001)	


Examiner Signature	Eileen B. O'Hara	Date Considered	10/4/05
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



FORM PTO-1449

INFORMATION DISCLOSURE STATEMENTATTY. DOCKET NO.
1488.1280006APPLICATION NO.
09/826,212APPLICANT
Wei et al.FILING DATE
April 5, 2001GROUP
1646

TECH CENTER 1646/2900

OCT 03 2001

RECEIVED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	REMARKS
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

EJA	AR	8	GenBank Accession No. AF016267, Schneider, P. et al., October 16, 1997.
EJA	AS	8	Co-Pending U.S. Patent Application No. 09/573,986, filed May 18, 2000. do not print
	AT		

EXAMINER

Eileen B. O'Hara

DATE CONSIDERED

2/28/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.1280006/EKS/EJH/SJE	APPLICATION NO. 09/826,212
	APPLICANT Wei et al.	
	FILING DATE April 5, 2001	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

EA	AR	2	Pending Non-Provisional U.S. Patent Application No. 09/912,293, filed July 26, 2001, pages 1-75 (pages 1 and 2 partially redacted); portion of Table 2; and SEQ ID No. 194270 (NOT PUBLISHED). <i>Do not print</i>
	AS		
	AT		

EXAMINER

Eileen B. O'Hara

DATE CONSIDERED

2/28/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 FIRST SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 1488.1280006/EKS/EJH/SJE	APPLICATION NO. 09/826,212
	APPLICANT Wei et al.	
	FILING DATE April 5, 2001	GROUP 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION
	AL						Yes No
	AM						Yes No
	AN						Yes No
	AO						Yes No
	AP						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR		
	AS		
EPA	AT	8	<i>do not print</i> Pending Non-Provisional U.S. Patent Application No. 09/912,292, filed July 26, 2001, pages 1-75 (pages 1 and 2 partially redacted); portion of Table 2; and SEQ ID Nos. 40587, 12875, and 53156 (NOT PUBLISHED).

EXAMINER <i>Ellen B. O'Hara</i>	DATE CONSIDERED <i>2/28/03</i>
------------------------------------	-----------------------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

File Copy